Acute Porphyria Drug Database

C09AA05 - Ramipril
Propably not porphyrinogenic
PNP

Rationale
No data pointing to CYP-interactions. One reference stating probable non-porphyrinogenicity. Risk for gastrointestinal adverse events in the form of digestive disturbances, dyspepsia, diarrhoea, nausea and vomiting motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
Alanine derivative which is hydrolyzed in the liver giving rise to the ACE- inhibitor ramiprilate. Also other metabolites are produced. No data pointing to CYP-interactions. South African list: use with care.
Therapeutic characteristics
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are abdominal pain, dyspepsia, diarrhoea, nausea and vomiting. Other common side effects are muscle spasms, myalgia, headache and fatigue.
IPNet drug reports
Uneventful use reported in 29 patients with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes C09A / C09AA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙